Subscribe to our Newsletters !!
Climate change is very disruptive to the Amazon ra
By 2024, there are certain things you need to do i
Insects that are given more attention and reverenc
Alembic Pharmaceuticals Limited appoints Mr. Manis
The importance of comparing the treatment of asthm
It is important to understand that natural remedie
Dear Readers, Welcome to the latest issue of The Magazine
Mumbai, April 12, 2019 – Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) announces that it has launched Niveoli™, India’s first extra-fine particle beclomethasone-formoterol combination hydrofluoroalkane (HFA) inhaler for adults, targeting drug delivery to the small airways. Niveoli™ is a proprietary Cipla inhaler, and the latest offering from Cipla in respiratory inhalation therapy that addresses an unmet need associated with obstructive airway diseases (OAD) such as asthma and chronic obstructive pulmonary disorder (COPD).
Asthma and COPD are lung conditions that affect the ability to breathe. Extensive research and an evolved understanding of the diseases over the years has shown the significant role of small airway disease in asthma and COPD. A recent meta-analysis showed that small airway disease is prevalent in 50-60% of asthma patients[1]. Another study has indicated that routine lung function tests can underestimate problems in the small airways[2]. Small airway disease is a common feature of COPD and gets worse with increasing severity of the condition[3]. Niveoli™’s novelty and strength lies in HFA propelled delivery of extra-fine particles of beclomethasone, an inhaled corticosteroid (ICS) and formoterol, a fast-onset long acting beta agonist (LABA) to the small airways.
Commenting on the launch, Nikhil Chopra,
